Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429788 | 0.78 | HTT (0.39) | SLC22A2CYP3A4TMEM97ABCG2HTT | |
| SCHEMBL3906226 | 0.73 | ALDH1A1 (0.38) | GRM2HTT | |
| SCHEMBL4218947 | 0.72 | MEN1 (0.38) | HTT | |
| SCHEMBL4196571 | 0.70 | POLB (0.43) | GRM2HTT | |
| SCHEMBL2185540 | 0.70 | SLC22A2 (0.50) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17748224 | 0.69 | SLC22A2 (0.45) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL2679427 | 0.68 | SLC22A2 (0.45) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL3912851 | 0.68 | HTT (0.44) | GRM2HTT | |
| SCHEMBL6408303 | 0.68 | AKR1B1 (0.47) | GRM2HTT | |
| SCHEMBL14107106 | 0.67 | MEN1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539714-B1 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20050288293-A1 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288293-A1 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | TYMP, TOP1, REV1 | GRM2 4299/4885SLC22A2 3675/4885CYP3A4 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.